Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

被引：998

作者：

Cully, M

You, H

Levine, AJ

Mak, TW

机构：

[1] Canc Inst New Jersey, New Brunswick, NJ USA

[2] Inst Adv Study, Princeton, NJ 08540 USA

来源：

NATURE REVIEWS CANCER | 2006年 / 6卷 / 03期

关键词：

D O I：

10.1038/nrc1819

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The tumour-suppressor phosphatase with tensin homology (PTEN) is the most important negative regulator of the cell-survival signalling pathway initiated by phosphatidylinositol 3-kinase (PI3K). Although PTEN is mutated or deleted in many tumours, deregulation of the PI3K-PTEN network also occurs through other mechanisms. Crosstalk between the PI3K pathways and other tumorigenic signalling pathways, such as those that involve Ras, p53, TOR (target of rapamycin) or DJ1, can contribute to this deregulation. How does the PI3K pathway integrate signals from numerous sources, and how can this information be used in the rational design of cancer therapies?

引用

收藏

页码：184 / 192

页数：9

相关论文

共 103 条

[1]

Abate-Shen C, 2003, CANCER RES, V63, P3886

[2] FoxOs at the crossroads of cellular metabolism, differentiation, and transformation [J].

Accili, D ;

Arden, KC .

CELL, 2004, 117 (04) :421-426

[3] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[4] Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials [J].

Bell, DW ;

Lynch, TJ ;

Haserlat, SM ;

Harris, PL ;

Okimoto, RA ;

Brannigan, BW ;

Sgroi, DC ;

Muir, B ;

Riemenschneider, MJ ;

Iacona, RB ;

Krebs, AD ;

Johnson, DH ;

Giaccone, G ;

Herbst, RS ;

Manegold, C ;

Fukuoka, M ;

Kris, MG ;

Baselga, J ;

Ochs, JS ;

Haber, DA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :8081-8092

[5] A portrait of AKT kinases - Human cancer and animal models depict a family with strong individualities [J].

Bellacosa, A ;

Testa, JR ;

Moore, R ;

Larue, L .

CANCER BIOLOGY & THERAPY, 2004, 3 (03) :268-275

[6] Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism [J].

Bonifati, V ;

Rizzu, P ;

van Baren, MJ ;

Schaap, O ;

Breedveld, GJ ;

Krieger, E ;

Dekker, MCJ ;

Squitieri, F ;

Ibanez, P ;

Joosse, M ;

van Dongen, JW ;

Vanacore, N ;

van Swieten, JC ;

Brice, A ;

Meco, G ;

van Duijn, CM ;

Oostra, BA ;

Heutink, P .

SCIENCE, 2003, 299 (5604) :256-259

[7] Oncogene-induced senescence as an initial barrier in lymphoma development [J].

Braig, M ;

Lee, S ;

Loddenkemper, C ;

Rudolph, C ;

Peters, AHFM ;

Schlegelberger, B ;

Stein, H ;

Dörken, B ;

Jenuwein, T ;

Schmitt, CA .

NATURE, 2005, 436 (7051) :660-665

[8] Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer [J].

Chan, S .

BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1420-1424

[9] Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer [J].

Chan, S ;

Scheulen, ME ;

Johnston, S ;

Mross, K ;

Cardoso, F ;

Dittrich, C ;

Eiermann, W ;

Hess, D ;

Morant, R ;

Semiglazov, V ;

Borner, M ;

Salzberg, M ;

Ostapenko, V ;

Illiger, HJ ;

Behringer, D ;

Bardy-Bouxin, N ;

Boni, J ;

Kong, S ;

Cincotta, M ;

Moore, L .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5314-5322

[10] Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit [J].

Chan, TO ;

Rodeck, U ;

Chan, AM ;

Kimmelman, AC ;

Rittenhouse, SE ;

Panayotou, G ;

Tsichlis, PN .

CANCER CELL, 2002, 1 (02) :181-191

← 1 2 3 4 5 6 7 8 9 10 →